Wintering A, Ishiyama K, Tamaki S, Tamaki C, Fandel J, Ji L, Wood BL, Shah NN, Yuan CM, O’Brien MM, Loh ML, Diaz-Flores E. CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2023 Jan 24;7(2):251-255. doi: 10.1182/bloodadvances.2021006810. PubMed PMID: 35500285; PubMed Central PMCID: PMC9840233.
Study ID Citation
Abstract
No abstract provided.